Author:
Doohan Peter T.,Oldfield Lachlan D.,Arnold Jonathon C.,Anderson Lyndsey L.
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf [Internet]. John Wiley and Sons Ltd; 2014 [cited 2021 4];23:489–97. Available from: https://pubmed.ncbi.nlm.nih.gov/24616171/
2. Watanabe JH, McInnis T, Hirsch JD. Cost of prescription drug–related morbidity and mortality. Ann Pharmacother. 2018;52:829–37.
3. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther [Internet]. Elsevier Inc.; 2013;138:103–41. Available from: https://doi.org/10.1016/j.pharmthera.2012.12.007
4. Anderson LL, Absalom NL, Abelev S V., Low IK, Doohan PT, Martin LJ, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia [Internet]. 2019 [cited 2019 Oct 20];epi.16355. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/epi.16355
5. Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28:332–8.
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献